ATE454901T1 - Verfahren zur erhaltung zellimmuneantworten gegen proteinen - Google Patents
Verfahren zur erhaltung zellimmuneantworten gegen proteinenInfo
- Publication number
- ATE454901T1 ATE454901T1 AT00968937T AT00968937T ATE454901T1 AT E454901 T1 ATE454901 T1 AT E454901T1 AT 00968937 T AT00968937 T AT 00968937T AT 00968937 T AT00968937 T AT 00968937T AT E454901 T1 ATE454901 T1 AT E454901T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- immune responses
- cell immune
- maintaining cell
- vertebrate subject
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15929899P | 1999-10-13 | 1999-10-13 | |
PCT/US2000/028040 WO2001026681A2 (en) | 1999-10-13 | 2000-10-10 | Method of obtaining cellular immune responses from proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE454901T1 true ATE454901T1 (de) | 2010-01-15 |
Family
ID=22571953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00968937T ATE454901T1 (de) | 1999-10-13 | 2000-10-10 | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
Country Status (10)
Country | Link |
---|---|
US (2) | US6534064B1 (de) |
EP (1) | EP1221968B1 (de) |
JP (2) | JP2003511420A (de) |
AT (1) | ATE454901T1 (de) |
AU (1) | AU7877900A (de) |
CA (1) | CA2388676A1 (de) |
DE (1) | DE60043708D1 (de) |
ES (1) | ES2337017T3 (de) |
PT (1) | PT1221968E (de) |
WO (1) | WO2001026681A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
ES2283012T3 (es) * | 1996-01-04 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | Bacterioferritina de helicobacter pylori. |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9807721D0 (en) * | 1998-04-08 | 1998-06-10 | Chiron Spa | Antigen |
EP1141314A2 (de) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon |
PT1221968E (pt) * | 1999-10-13 | 2010-04-16 | Novartis Vaccines & Diagnostic | Processo de obtenção de respostas imunes celulares de proteínas |
DE60117164T2 (de) * | 2000-11-07 | 2006-08-03 | Immuno Vaccine Technologies Inc., Halifax | Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung |
DE60239317D1 (de) * | 2001-01-12 | 2011-04-14 | Novartis Vaccines & Diagnostic | Nukleinsäure mukosale immunisierung |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
ITRM20010336A1 (it) * | 2001-06-13 | 2002-12-13 | Biostrands S R L | Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi |
WO2002102407A1 (en) * | 2001-06-15 | 2002-12-27 | Nordic Vaccine Technology A/S | Therapeutical vaccination |
CA2451739A1 (en) * | 2001-06-29 | 2003-01-09 | Chiron Corporation | Hcv e1e2 vaccine compositions |
AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP1423142A1 (de) * | 2001-08-31 | 2004-06-02 | Chiron SRL. | Helicobacter pylori impfung mit einer kombination der proteine caga, vaca und nap |
CN1599623B (zh) | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | 免疫刺激物向病毒样颗粒内的包装:制备方法与用途 |
JP2005519619A (ja) * | 2002-03-13 | 2005-07-07 | 麒麟麦酒株式会社 | インフルエンザm2タンパク質に対するヒトモノクローナル抗体および上記抗体を作製しかつ利用する方法 |
EP1490083A1 (de) | 2002-03-29 | 2004-12-29 | The Regents of the University of California | Mikrogelteilchen zur abgabe von biologisch wirksamen materialien |
JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
JP2006520746A (ja) * | 2002-12-27 | 2006-09-14 | カイロン コーポレイション | リン脂質を含む免疫原性組成物 |
EP1610757A4 (de) * | 2003-04-10 | 2007-05-30 | Transform Pharmaceuticals Inc | Profilierung von konformationsvarianten, antikörper-zusammensetzungen und anwendungsverfahren dafür |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
FR2859909B1 (fr) * | 2003-09-22 | 2007-09-07 | Biomerieux Sa | Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation |
US20070020238A1 (en) * | 2005-06-01 | 2007-01-25 | David Baltimore | Method of targeted gene delivery using viral vectors |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
CA2626257A1 (en) * | 2005-10-17 | 2007-04-26 | Novartis Ag | Multiclade hiv vaccines |
JP5484732B2 (ja) | 2005-12-14 | 2014-05-07 | サイトス バイオテクノロジー アーゲー | 過敏症の治療のための免疫賦活性核酸パッケージ粒子 |
ES2427994T3 (es) | 2006-06-12 | 2013-11-05 | Cytos Biotechnology Ag | Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN |
PT2520168E (pt) * | 2006-07-21 | 2014-04-29 | California Inst Of Techn | Administração de gene alvo para vacinação de células dendríticas |
AU2007333147B2 (en) | 2006-12-12 | 2013-12-19 | Kuros Us Llc | Oligonucleotides containing high concentrations of guanine monomers |
JP5731198B2 (ja) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用 |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
AU2008335457B2 (en) | 2007-12-07 | 2015-04-16 | Glaxosmithkline Biologicals S.A. | Compositions for inducing immune responses |
JP5715051B2 (ja) | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
EP2315571A4 (de) * | 2008-07-16 | 2013-05-01 | Surmodics Pharmaceuticals Inc | Verfahren zur herstellung von mikropartikeln mit bioaktiven peptiden |
DK2770061T3 (en) | 2009-07-24 | 2019-01-07 | Immune Design Corp | NON-INTEGRATING LENTIVIRUS VECTORS |
EP3187585A1 (de) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
MX362699B (es) | 2012-03-30 | 2019-02-01 | Immune Design Corp | Partículas de vectores lentivirales teniendo eficiencia de transducción mejorada para células que expresan dc-sign. |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
US20130302366A1 (en) * | 2012-05-09 | 2013-11-14 | Christopher Marshall | Conformationally Specific Viral Immunogens |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
WO2018055535A2 (en) | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2750045A1 (de) * | 1977-11-09 | 1979-05-10 | Behringwerke Ag | Verfahren zur entfernung von detergentien aus virusantigensuspensionen |
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
JPS62138500A (ja) * | 1985-12-11 | 1987-06-22 | Sumitomo Pharmaceut Co Ltd | ポリペプチドの製法 |
JPH01500999A (ja) * | 1986-10-20 | 1989-04-06 | チロン コーポレイション | Hsvの治療的処置に用いるワクチン |
JPH0751513B2 (ja) * | 1988-04-28 | 1995-06-05 | 国立予防衛生研究所長 | A型肝炎ワクチン |
CA2037151A1 (en) * | 1990-03-23 | 1991-09-24 | F. Hoffmann-La Roche Ag | Plasmodium sporozoite antigen |
EP0565794A1 (de) * | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induktion von CTL-Antworten |
US5928647A (en) * | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
ZA982763B (en) * | 1997-04-09 | 1998-10-05 | Akzo Nobel Nv | Vaccines |
EP0980257A1 (de) | 1997-05-01 | 2000-02-23 | Chiron Corporation | Verwendung von virusähnlichen partikeln als adjuvantien |
EP0913479A3 (de) * | 1997-10-27 | 2000-10-25 | Smithkline Beecham Corporation | Adenin Glycosylase |
PT1042001E (pt) * | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
US6635257B1 (en) * | 1998-06-24 | 2003-10-21 | Innogentics N.V. | Particles of HCV envelope proteins: use for vaccination |
PT1221968E (pt) * | 1999-10-13 | 2010-04-16 | Novartis Vaccines & Diagnostic | Processo de obtenção de respostas imunes celulares de proteínas |
-
2000
- 2000-10-10 PT PT00968937T patent/PT1221968E/pt unknown
- 2000-10-10 US US09/686,345 patent/US6534064B1/en not_active Expired - Lifetime
- 2000-10-10 AU AU78779/00A patent/AU7877900A/en not_active Abandoned
- 2000-10-10 JP JP2001529742A patent/JP2003511420A/ja not_active Withdrawn
- 2000-10-10 AT AT00968937T patent/ATE454901T1/de active
- 2000-10-10 EP EP00968937A patent/EP1221968B1/de not_active Expired - Lifetime
- 2000-10-10 CA CA002388676A patent/CA2388676A1/en not_active Abandoned
- 2000-10-10 DE DE60043708T patent/DE60043708D1/de not_active Expired - Lifetime
- 2000-10-10 WO PCT/US2000/028040 patent/WO2001026681A2/en active Application Filing
- 2000-10-10 ES ES00968937T patent/ES2337017T3/es not_active Expired - Lifetime
-
2003
- 2003-01-08 US US10/340,034 patent/US7604802B2/en not_active Expired - Fee Related
-
2011
- 2011-03-22 JP JP2011063393A patent/JP2011116796A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2001026681A3 (en) | 2002-01-31 |
US20030104067A1 (en) | 2003-06-05 |
PT1221968E (pt) | 2010-04-16 |
JP2003511420A (ja) | 2003-03-25 |
US7604802B2 (en) | 2009-10-20 |
AU7877900A (en) | 2001-04-23 |
EP1221968A2 (de) | 2002-07-17 |
JP2011116796A (ja) | 2011-06-16 |
US6534064B1 (en) | 2003-03-18 |
CA2388676A1 (en) | 2001-04-19 |
EP1221968B1 (de) | 2010-01-13 |
DE60043708D1 (de) | 2010-03-04 |
WO2001026681A2 (en) | 2001-04-19 |
ES2337017T3 (es) | 2010-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE454901T1 (de) | Verfahren zur erhaltung zellimmuneantworten gegen proteinen | |
AU2903999A (en) | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines | |
IL132468A0 (en) | A kit for inducing immune response against a tumor or a disease caused by an infection agent | |
EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
EP2325205A3 (de) | Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung | |
DK0757717T3 (da) | Papillomavirusvacciner | |
AU2001265346A1 (en) | Artificial antigen presenting cells and methods of use thereof | |
ATE236255T1 (de) | Impfstoff gegen den hepatitis e-virus und verfahren | |
DE69930630D1 (de) | B2microglobulin fusionsproteine und varianten mit hoher affinität | |
JP2003515569A5 (de) | ||
WO2002088328A8 (en) | Method for generating highly active human dendritic cells from monocytes | |
DE60331725D1 (de) | Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren | |
DE69933875D1 (de) | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. | |
EP1801123A3 (de) | Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung | |
ATE341339T1 (de) | Zusammensetzungen von rekombinanten papillomavirus vakzinen | |
ATE310750T1 (de) | Verotoxin b untereinheit zur immunisierunug | |
DE602004015141D1 (de) | Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe | |
AU7546500A (en) | Designing immunogens | |
EP1131338A4 (de) | Methode für die herstellung von gereinigtem invasinprotein und seine anwendung | |
ATE385809T1 (de) | Saponin-zusammensetzungen und deren verwendung | |
DE602004019141D1 (de) | Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide | |
AU2002221553A1 (en) | Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use | |
DE59704883D1 (de) | Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen | |
ATE359092T1 (de) | Verfahren zur herstellung pharmazeutischer formulierungen | |
WO2004035003A3 (en) | Therapeutic adjuvant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1221968 Country of ref document: EP |